Santen Pharmaceutical updates on share buyback and performance-linked stock disposal

Santen Pharmaceutical Co., Ltd. announced that it repurchased 5,236,000 common shares totaling JPY 8,248,657,100 from August 1 to August 31, 2025. This is part of a larger plan, approved on May 13, 2025, to acquire up to 19,800,000 shares for a maximum of JPY 35 bn, with an acquisition period running from May 22 to November 5, 2025. As of August 31, 2025, Santen has cumulatively repurchased 13,803,400 shares for JPY 22,389,045,300.

In a separate announcement on September 3, 2025, Santen detailed the disposal of 57,909 treasury shares, valued at JPY 1,600.5 per share, totaling JPY 92,683,353. These shares, disposed on September 30, 2025, are allocated as performance-linked stock remuneration for the FY2022-2024 period. The remuneration plan’s payout ratio was 142.6%, based on performance metrics including relative TSR and ESG-related metrics.

This disposal aims to provide medium-to-long-term incentives and align shareholder value. The allocation includes 11,918 shares for two directors (excluding outside directors), 18,529 shares for four corporate officers, and 27,462 shares for two leavers.